Sterling Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Sterling Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.71K	Buy	2,020 +1,804	+835%	+$10.5K	﹤0.01%	2587
2026 Q2	$1.73K	Sell	216 -167	-44%	-$1.44K	﹤0.01%	3029
2026 Q1	$3.08K	Sell	383 -19	-5%	-$182	﹤0.01%	2886
2025 Q4	$4.68K	Buy	402 +259	+181%	+$2.52K	﹤0.01%	2911
2025 Q3	$1.44K	Buy	143 +10	+8%	+$144	﹤0.01%	3025
2025 Q2	$2.32K	Buy	133 +82	+161%	+$1.18K	﹤0.01%	2882
2025 Q1	$642	Hold	51	–	–	﹤0.01%	2923
2024 Q4	$538	Hold	51	–	–	﹤0.01%	3022
2024 Q3	$740	Buy	+51	New	+$607	﹤0.01%	2689

Other funds holding SPRY

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Norman Fields Gottscho Capital Management New York $329M AUM 22.06% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

USAdvisors Wealth Management Eden Prairie, Minnesota $351M AUM 13.01% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return

CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Sterling Capital Management's SPRY Position: Q3 2026 in Review

Sterling Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 835% in Q3 2026, buying an estimated $10.5K and bringing the position to 2,020 shares worth $8.71K. The position accounts for ﹤0.01% of the portfolio, ranked #2587.

Sterling Capital Management first reported a position in SPRY in Q3 2024 and has held it in 9 quarters since. 26 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

Sterling Capital Management held 2,020 shares of ARS Pharmaceuticals worth $8.71K as of Q3 2026.
Sterling Capital Management bought 1,804 ARS Pharmaceuticals shares in Q3 2026, an estimated $10.5K.
ARS Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2587 holding.
Sterling Capital Management first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
26 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.